Epigenomic and machine learning models to predict pancreatic cancer
IMAGene is a European Project funded under the framework of the ERA-PerMed call “Multidisciplinary research projects on personalised medicine – development of clinical support tools for personalised medicine implementation”. The consortium gathers 20 partners located in Europe with different expertise and the common aim to develop, implement and test a comprehensive Cancer Risk prediction Algorithm to predict Pancreatic Cancer in high-risk asymptomatic subjects. Nowadays pancreatic cancer has the lowest survival rate of all cancers in Europe, with no early detection strategies available.
Era PerMed project funded in the 2021 Joint Transnational Call for Proposals (JTC 2021) co-funded by the European Commission/DG Research and Innovation
Website: https://www.imagene.ieo.eu/
Period: 01/04/2022 - 30/09/2025
This study has been funded by Instituto de Salud Carlos III through the project AC21_2/00013, under the frame ERA PerMed program. Funded by European Union - NextGenerationEU. We thank CERCA Programme / Generalitat de Catalunya for institutional support.
This study has been funded by AECC Scientific Foundation through the project AC21_2/00013, under the frame ERA-NET PerMed program. We thank CERCA Programme / Generalitat de Catalunya for institutional support.
